<DOC>
	<DOCNO>NCT00480116</DOCNO>
	<brief_summary>The study vaccine develop use pre-dialysis/ haemodialysis patient immuno-compromised individual could sub-optimal response follow vaccination hepatitis B currently available commercial vaccine ( target population ) . This study aim confirm clinical setting consistency production three lot vaccine .</brief_summary>
	<brief_title>Consistency Study Three Lots Henogen 's Adjuvanted Hepatitis B Vaccine When Given 0 , 1 Month Schedule</brief_title>
	<detailed_description>Double-blind , randomise , single centre study three group receive three different lot Henogen 's adjuvanted hepatitis B vaccine accord 0 , 1 month schedule . Blood sample take Month 0 , Months 1 2 .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A healthy male female adult age 18 40 year . Written inform consent obtain subject Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug within six month prior first vaccine dose . Administration vaccine foreseen study protocol within 14 day ( kill vaccine ) 30 day ( attenuated/ live vaccine ) first vaccine dose . Concurrently participate another clinical study exposure investigational noninvestigational product ( pharmaceutical product device ) . History hepatitis B infection . Known exposure hepatitis B virus within 6 month . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . Pregnant lactate female . Female plan become pregnant planning discontinue contraceptive precaution .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>Consistency</keyword>
	<keyword>Immunogenicity</keyword>
</DOC>